03:44 PM EST - PharmaGap Inc. : said results from the initial testing of cancer drug GAP-107B8 by the U.S. National Cancer Institute showed significant inhibition of cancer cell growth at a low drug concentration, 10 micronsM, across a wide range of human cancer cell lines that comprise the NCI-60 panel. As currently configured, the NCI-60 panel is comprised of 57 human cancer cell lines derived from nine different cancers - breast, prostate, renal, ovarian, CNS, colon, lung, melanoma and leukemia. The company indicated that GAP-107B8 demonstrated greater than 50% inhibition in cancer cell growth in 26 of 57 cell lines, 46% of all cell lines, from all nine cancer types in the panel. PharmaGap Inc.
shares V.GAP are trading down $0.015 at $0.35.
